Clinical Edge Journal Scan

Variation in risk profiles of early RA treatment regimens


 

Key clinical point: Early rheumatoid arthritis (RA) strategies have different risk profiles. Moreover, the use of early steroid-based regimens did not emerge as more harmful.

Major finding: The risk for serious adverse events was higher with biologic monotherapy vs. methotrexate (MTX)+steroid therapy (rate ratio [RR], 3.22; 95% confidence interval [CI], 1.47-7.07) and with biological monotherapy vs. MTX monotherapy (RR, 1.39; 95% CI, 1.12-1.73) and MTX+biologic disease-modifying antirheumatic drugs (DMARD; RR, 1.26; 95% CI, 1.02-1.54).

Study details: Findings are from a network meta-analysis of 20 double-blind randomized clinical trials involving 9,202 adult patients with RA who were initiated on DMARD therapy.

Disclosures: This study received no external funding. The authors received speaker’s fees and honoraria from various pharmaceutical companies including AbbVie. None of the authors reported any conflict of interest.

Source: Adas MA et al. Rheumatology (Oxford). 2021 May 18. doi: 10.1093/rheumatology/keab429 .

Recommended Reading

MTX+LEF combo shows robust safety profile compared with other therapeutic regimens in RA
MDedge Rheumatology
aIL-6 more effective than bDMARDs in RA with knee joint involvement
MDedge Rheumatology
RA: Obesity tied to lower odds of remission and more intensive csDMARD exposure
MDedge Rheumatology
Distinct clinical and biomechanical factors could help identify RA patients at risk for falls
MDedge Rheumatology
RA: TNFi is the most preferred therapeutic option for patients with inadequate methotrexate response
MDedge Rheumatology
Clinical Edge Commentary: RA June 2021
MDedge Rheumatology
RA: Tofacitinib modified-release 11 mg OD plus methotrexate shows promise in ORAL Shift trial
MDedge Rheumatology
Worse COVID-19 outcomes in RA patients treated with rituximab and JAKi
MDedge Rheumatology
Additional cardiovascular benefits of methotrexate in RA
MDedge Rheumatology
Tocilizumab raises risk of diverticulitis and GI perforation vs. rituximab and abatacept in RA
MDedge Rheumatology